Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide is a once-weekly medicine — taking it twice a week is not how it is licensed, not how it works clinically, and not something a prescriber should approve. The molecule is designed with a half-life long enough to keep working across a full seven days, so doubling up does not double the benefit. It does raise the risk of side effects meaningfully. As a prescription-only medicine, the dose and frequency are decided by a clinician after reviewing your full health picture, not chosen by the patient at home. If your current dose feels like it isn't doing enough, that's a conversation worth having with your prescriber — but the answer is almost never a second injection mid-week.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's a logical leap. If one injection a week produces weight loss, two injections must produce more. In practice, that's not how tirzepatide behaves. The medicine is engineered to sit in the body for days at a time, its pharmacokinetic profile peaks within roughly 24 hours of injection and then declines slowly over the rest of the week. By the time your next dose is due, concentrations are lower but still active. A second injection three or four days in doesn't top up an empty tank; it stacks on top of levels that haven't cleared yet.
The clinical trials that earned tirzepatide its UK licence (including SURMOUNT-1, published in the New England Journal of Medicine) were run entirely on a once-weekly schedule. The weight-loss results seen in those trials, averaging around 20–21% body weight reduction at the highest dose over 72 weeks, came from that schedule alone. There are no comparable data for twice-weekly dosing in this context, and NHS guidance on tirzepatide is clear that the prescribed interval should be followed exactly.
If you're wondering whether taking Mounjaro twice a week could speed things up, the timing question is understandable. But frequency isn't the lever your prescriber will pull.
Taking tirzepatide more often than prescribed doesn't accelerate fat loss, it accelerates side effects. Gastrointestinal symptoms (nausea, vomiting, diarrhoea, stomach cramps) are already among the most common reasons people reduce their dose or pause treatment. These effects are dose-related: the higher the circulating level of the medicine, the more pronounced they tend to be, particularly in the early weeks. A second injection would push exposure well beyond the studied range.
There's also a practical downstream problem. If you inject twice a week, your supply runs out ahead of schedule. Reordering early isn't straightforward when the prescription is clinically reviewed before each repeat, as it should be. You'd be in a gap without medicine, and irregular dosing creates its own issues. Consistency matters more than frequency for this kind of treatment.
Our page on taking tirzepatide a day early covers what a small shift in injection day means in practice, which is quite different from halving the interval altogether.
The feeling that treatment isn't doing enough is common, especially in the early weeks at 2.5 mg, a starting dose designed to let your body adjust, not to produce the full effect. Progress comes through the titration schedule, moving up through the dose steps as your prescriber assesses tolerability and response. That process is intentional and evidence-based, not a holding pattern.
If you're several months in, on a maintenance dose, and feel weight loss has plateaued, there are real clinical options: checking whether the dose can move higher, reviewing dietary patterns alongside the medicine, or looking at what else might be affecting progress. Those conversations belong with your prescriber. They won't suggest injecting twice a week, but they may well have useful suggestions your current routine doesn't include.
Our clinical team at nume reviews every consultation personally, a real clinician reads your answers, not software. Questions about how your treatment is going are exactly what that review is for. You can also read more about the Mounjaro treatment overview or check the broader tirzepatide guidance if you're still weighing up whether this treatment is right for you.
One thing worth knowing about the schedule more broadly: there is some flexibility around the exact day, injecting every six days occasionally is a different situation from injecting twice in the same week, and your Patient Information Leaflet addresses that distinction. For specific eligibility questions, our BMI and Mounjaro eligibility guide explains what clinical thresholds apply in a UK private setting. And if cost is part of the picture, the treatment page sets out exactly what's included in the price, no surprises mid-way through.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.